8-K: EyePoint Completes Phase 3 DME Trial Enrollment Ahead of Schedule

EyePoint, Inc. announced the completion of enrollment in its pivotal Phase 3 clinical trials for DURAVYU in treating diabetic macular edema (DME), with topline data expected in Q4 2027.

Summary

• EyePoint, Inc. has successfully completed enrollment for both of its pivotal Phase 3 clinical trials, COMO and CAPRI, evaluating DURAVYU for the treatment of diabetic macular edema (DME).
• Over 480 participants were enrolled across both trials in just five months, ahead of the anticipated schedule.
• Topline data from these trials are expected in the fourth quarter of 2027.
• DURAVYU is an investigational sustained-delivery treatment combining vorolanib with Durasert E technology, designed for at least six months of drug release.
• The trials are randomized, double-masked, on-label 2mg aflibercept controlled non-inferiority Phase 3 trials assessing DURAVYU's safety and efficacy.
• DURAVYU targets VEGF, PDGF, and inflammation via IL-6/JAK1 signaling.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the ahead-of-schedule enrollment and strong trial execution, though the ultimate success hinges on future data and regulatory approval.

Positives

• Enrollment in both pivotal Phase 3 DME trials (COMO and CAPRI) was completed ahead of schedule, in only five months.
• Over 480 participants were enrolled across the two trials.
• The company expresses confidence in DURAVYU's potential due to its efficacy, safety profile, and positive feedback from regulatory bodies (FDA and EMA).
• A Data Safety Monitoring Committee (DSMC) recommended continuation of both wet AMD and DME Phase 3 programs without protocol modifications after reviewing masked safety data.
• DURAVYU has demonstrated a favorable safety and tolerability profile in over 190 patients across four completed clinical trials, with no observed DURAVYU-related safety concerns.

Negatives

• Topline data from the Phase 3 DME trials is not expected until the fourth quarter of 2027, indicating a significant time lag before key results are available.
• DURAVYU is an investigational product and has not yet been approved by the FDA; approval and its timeline are uncertain.

Risks

• Uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval for DURAVYU.
• The risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data observed during clinical trials.
• Changes in the regulatory environment or disruptions at the FDA.
• Delays, interruptions, or failures in the manufacture and supply of product candidates, including due to unanticipated regulatory compliance issues or warning letters.
• The availability of and need for additional financing to support clinical development programs.

Future Outlook

Topline data for the pivotal Phase 3 clinical trials evaluating DURAVYU for diabetic macular edema (DME) is anticipated in the fourth quarter of 2027. Data from the Phase 3 wet age-related macular degeneration (wet AMD) program is expected to be reported beginning in August 2026. The company's cash runway is mentioned as a factor in its financial position, with potential need for additional financing.

Management Comments

• "Completing enrollment across both COMO and CAPRI ahead of expectations is a testament to our team's exceptional execution and dedication to delivering a potentially more durable and differentiated treatment option for patients with DME, the second largest retinal disease market," said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint.
• "DURAVYU's compelling efficacy and safety profile, combined with positive feedback on our trial design from both the FDA and EMA, underscores our confidence in the program as we advance toward topline data in DME anticipated next year."
• "Today's milestone represents an important advancement for the retina community, as DME patients remain chronically undertreated given the current frequent and burdensome injection schedule," said Veeral Sheth, M.D., Partner and Director of Clinical Research at University Retina and Macula Associates.
• "The rapid enrollment of COMO and CAPRI highlights the excitement in the community to potentially utilize DURAVYU's sustained drug delivery and multi-mechanism of action... to provide more durable outcomes for DME patients."

Industry Context

StockSavvy.ai notes that the rapid enrollment ahead of schedule in these pivotal Phase 3 trials for DURAVYU in diabetic macular edema (DME) suggests strong interest from both the medical community and patients in novel treatment options for this significant retinal disease market. The multi-mechanism of action of DURAVYU, targeting VEGF, PDGF, and inflammation, aligns with evolving understanding of DME's complex pathology beyond solely VEGF.

Stakeholder Impact

• Shareholders: Positive impact from achieving a key clinical trial milestone ahead of schedule, potentially increasing confidence in the company's pipeline and future prospects.
• Patients with DME: Potential future benefit from a new, potentially more durable and less burdensome treatment option if DURAVYU receives regulatory approval.
• Retinal Specialists: Enthusiasm for participating in trials and potential adoption of a new therapeutic modality for DME management.

Next Steps

• Anticipate topline data from the Phase 3 DME trials (COMO and CAPRI) in Q4 2027.
• Anticipate data reporting from the Phase 3 wet AMD program beginning in August 2026.
• Continue clinical development and regulatory interactions for DURAVYU.

Key Dates

Recommendation

The ahead-of-schedule enrollment is a positive operational achievement, but the stock recommendation remains 'hold' as critical topline data for the pivotal Phase 3 DME trials is not expected until late 2027. Significant uncertainty remains regarding regulatory approval and commercialization, and the company's financial runway may require future capital raises.

Keywords

Diabetic Macular Edema, DME, DURAVYU, vorolanib, Phase 3 clinical trials, retinal diseases, sustained delivery, intravitreal injection